Catalyst Pharmaceuticals Stock EBITDA
| CPRX Stock | USD 14.72 0.30 2.00% |
Catalyst Pharmaceuticals fundamentals help investors to digest information that contributes to Catalyst Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Catalyst Stock. The fundamental analysis module provides a way to measure Catalyst Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Catalyst Pharmaceuticals stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | 120 M | 126 M |
Catalyst | EBITDA |
Catalyst Pharmaceuticals Company EBITDA Analysis
Catalyst Pharmaceuticals' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Catalyst Pharmaceuticals EBITDA | 119.95 M |
Most of Catalyst Pharmaceuticals' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Catalyst Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Catalyst EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for Catalyst Pharmaceuticals is extremely important. It helps to project a fair market value of Catalyst Stock properly, considering its historical fundamentals such as EBITDA. Since Catalyst Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Catalyst Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Catalyst Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
Catalyst Ebitda
Ebitda |
|
According to the company disclosure, Catalyst Pharmaceuticals reported earnings before interest,tax, depreciation and amortization of 119.95 M. This is 86.33% lower than that of the Biotechnology sector and 19.77% higher than that of the Health Care industry. The ebitda for all United States stocks is 96.92% higher than that of the company.
Catalyst Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Catalyst Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Catalyst Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Catalyst Pharmaceuticals' value.| Shares | Northern Trust Corp | 2023-12-31 | 1.4 M | Jacobs Levy Equity Management, Inc. | 2023-09-30 | 1.3 M | Opaleye Management Inc | 2023-12-31 | 1.3 M | Lsv Asset Management | 0313-12-31 | 1.2 M | T. Rowe Price Associates, Inc. | 2023-12-31 | 1.2 M | Hhg Plc | 2023-12-31 | 1.1 M | Charles Schwab Investment Management Inc | 2023-12-31 | 956.3 K | Amvescap Plc. | 2023-12-31 | 919.6 K | American Century Companies Inc | 2023-12-31 | 917.6 K | Blackrock Inc | 2023-12-31 | 15.8 M | Deerfield Management Co | 2023-09-30 | 8.2 M |
Catalyst Fundamentals
| Return On Equity | 0.21 | ||||
| Return On Asset | 0.13 | ||||
| Profit Margin | 0.18 % | ||||
| Operating Margin | 0.38 % | ||||
| Current Valuation | 1.6 B | ||||
| Shares Outstanding | 118.01 M | ||||
| Shares Owned By Insiders | 6.21 % | ||||
| Shares Owned By Institutions | 73.38 % | ||||
| Number Of Shares Shorted | 6.27 M | ||||
| Price To Earning | 23.62 X | ||||
| Price To Book | 4.63 X | ||||
| Price To Sales | 4.51 X | ||||
| Revenue | 398.2 M | ||||
| Gross Profit | 160.02 M | ||||
| EBITDA | 119.95 M | ||||
| Net Income | 71.41 M | ||||
| Cash And Equivalents | 220.79 M | ||||
| Cash Per Share | 2.15 X | ||||
| Total Debt | 3.56 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 10.79 X | ||||
| Book Value Per Share | 3.62 X | ||||
| Cash Flow From Operations | 143.6 M | ||||
| Short Ratio | 5.42 X | ||||
| Earnings Per Share | 0.63 X | ||||
| Target Price | 26.71 | ||||
| Number Of Employees | 167 | ||||
| Beta | 0.88 | ||||
| Market Capitalization | 1.74 B | ||||
| Total Asset | 471.91 M | ||||
| Retained Earnings | 121.27 M | ||||
| Working Capital | 143.27 M | ||||
| Current Asset | 59.9 M | ||||
| Current Liabilities | 3.44 M | ||||
| Net Asset | 471.91 M |
About Catalyst Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Catalyst Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Catalyst Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Catalyst Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Catalyst Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Catalyst Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Catalyst Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Catalyst Stock
| 0.72 | RGC | Regencell Bioscience | PairCorr |
| 0.67 | GH | Guardant Health Financial Report 14th of May 2024 | PairCorr |
| 0.63 | OM | Outset MedicalInc | PairCorr |
| 0.57 | AMGN | Amgen Inc | PairCorr |
| 0.44 | PROC | Procaps Group SA Report 10th of May 2024 | PairCorr |
The ability to find closely correlated positions to Catalyst Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Catalyst Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Catalyst Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Catalyst Pharmaceuticals to buy it.
The correlation of Catalyst Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Catalyst Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Catalyst Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Catalyst Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Catalyst Pharmaceuticals Piotroski F Score and Catalyst Pharmaceuticals Altman Z Score analysis. For more information on how to buy Catalyst Stock please use our How to Invest in Catalyst Pharmaceuticals guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Complementary Tools for Catalyst Stock analysis
When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is Catalyst Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Catalyst Pharmaceuticals. If investors know Catalyst will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Catalyst Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.346 | Earnings Share 0.63 | Revenue Per Share 3.747 | Quarterly Revenue Growth 0.82 | Return On Assets 0.1283 |
The market value of Catalyst Pharmaceuticals is measured differently than its book value, which is the value of Catalyst that is recorded on the company's balance sheet. Investors also form their own opinion of Catalyst Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Catalyst Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Catalyst Pharmaceuticals' market value can be influenced by many factors that don't directly affect Catalyst Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Catalyst Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Catalyst Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Catalyst Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.